Physician profile
Steven Brozinsky
NPI 1649266834
$2,067.57
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $810 · 2020: $228 · 2021: $202 · 2022: $707 · 2024: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $120.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $597.27 | 2019-2024 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $368.11 | 2019-2022 | |
| Braintree Laboratories, INC. | $336.20 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $150.15 | 2019-2022 | |
| Abbvie INC. | $135.71 | 2019-2022 | |
| Gilead Sciences, INC. | $121.98 | 2019 | |
| Medtronic, INC. | $108.77 | 2022 | |
| Janssen Biotech, INC. | $88.81 | 2021-2022 | |
| Shionogi INC | $43.87 | 2019 | |
| Exelixis INC. | $39.06 | 2019 | |
| Romark Laboratories, Lc | $34.24 | 2019 | |
| Allergan, INC. | $16.40 | 2020 | |
| W. L. Gore & Associates, INC. | $14.88 | 2020 | |
| Redhill Biopharma INC. | $12.12 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Brozinsky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.